134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review
Authors: ABITBOL ALEXANDER , JAIN AKSHAY B. , TSOUKAS MICHAEL , SIGALAS JOHN , GALM BRANDON P. , LEE JOOHO , QURESHY KAMRAN S. , COLLINS CAITLYN , WOO VINCENT C. 
Published: June 2023

The change in HbA1c after initiating FreeStyle Libre or FreeStyle Libre 2 Flash Glucose Monitoring System (FSL and FSL2) in adults with type 2 diabetes (T2D) in a real-world setting was evaluated over a 3-6 month period. Nine sites in Canada collected medical record data prospectively for adults who had started FSL or FSL2 in the last 3 months and with the following criteria: a basal insulin regimen with or without additional glucose lowering medications, and HbA1c 8.0-12.0%. Preliminary data were analysed from 79/138 medical records (n=138; 6 records ineligible, 53 no follow up, ineligible HbA1c or had stopped FSL or FSL2). Participants had the following baseline characteristics (mean±SD): HbA1c 8.9%±0.8, age 67.3±11.5 years (57% ≥65 years), BMI 30.1±6.2 (n=65), insulin use duration 5.3±3.9 years, and 54% were males. The most commonly used non-insulin glucose lowering medications included metformin (87.3%), sodium-glucose co-transporter-2 (SGLT2) inhibitors (62.0%) and sulphonylureas (46.8%). By the end of the study (3-6 months after the index date), mean HbA1c was reduced by 0.6%±1.1 to 8.3%±1.0 (p&lt;0.0001). Observed changes in antihyperglycemic medications from baseline included increased use of GLP-1 agonists from 44.3% to 51.9% and decreased use of DPP4i from 24.1% to 16.5%. This prospective chart review study found that initiating intermittently scanned continuous glucose monitoring in individuals with T2D treated with basal insulin plus other glucose lowering medications was associated with significantly improved HbA1c over a 3-6 month period.

Disclosure
A. Abitbol: Advisory Panel; Abbott Diabetes, Lilly Diabetes, Dexcom, Inc., Novo Nordisk Canada Inc., Janssen Pharmaceuticals, Inc., Research Support; Abbott Diabetes, Lilly Diabetes, Zucara Therapeutics, Novo Nordisk Canada Inc., Moderna, Inc., Senseonics, Speaker's Bureau; Boehringer Ingelheim (Canada) Ltd., Lilly Diabetes, Amgen Canada, Dexcom, Inc., Novo Nordisk Canada Inc., HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Sanofi. A. B. Jain: Advisory Panel; Abbott, Amgen Canada, Dexcom, Inc., AstraZeneca, Novo Nordisk, Bayer Inc., Insulet Corporation, Takeda Canada, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Research Support; Abbott, Amgen Canada, Novo Nordisk, Speaker's Bureau; Abbott, Amgen Canada, Dexcom, Inc., AstraZeneca, Novo Nordisk, Bausch Health, Canada, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Pfizer Inc. M. Tsoukas: Speaker's Bureau; Novo Nordisk Canada Inc., Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Scientific Affairs, LLC, AstraZeneca, Sanofi. J. Sigalas: None. B. P. Galm: Advisory Panel; Abbott, Boehringer Ingelheim (Canada) Ltd., Novo Nordisk Canada Inc., Pfizer Inc., Research Support; Abbott, Speaker's Bureau; Abbott, Dexcom, Inc., Pfizer Inc. J. Lee: Advisory Panel; Amgen Canada, Research Support; Novo Nordisk, Lilly, Abbott, Speaker's Bureau; Amgen Canada, Canadian Collaborative Research Network, AstraZeneca, Pfizer Inc. K. S. Qureshy: Advisory Panel; Novo Nordisk, Other Relationship; Novo Nordisk, Novo Nordisk, Research Support; Abbott Diagnostics, Novo Nordisk, Speaker's Bureau; AstraZeneca. C. Collins: None. V. C. Woo: Advisory Panel; Abbott, Speaker's Bureau; Dexcom, Inc.

Funding
Abbott Diabetes Care